A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis - PubMed (original) (raw)
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis
Tobias Larsson et al. J Clin Endocrinol Metab. 2005 Apr.
Abstract
Gain-of-function mutations in fibroblast growth factor-23 (FGF23) are responsible for autosomal dominant hypophosphatemic rickets, a disorder of isolated renal phosphate wasting. Patients with the disorder display hypophosphatemia with normocalcemia as well as inappropriately normal 1,25-dihydroxyvitamin D [1,25(OH)2D3] concentrations. Reciprocally tumoral calcinosis (TC) patients are often hyperphosphatemic with inappropriately normal or elevated serum 1,25(OH)2D3 levels and have ectopic and vascular calcifications, a phenotype similar to that of Fgf23 null mice. Therefore, the goal of the present studies was to test whether FGF23 was a candidate gene for TC. Two sisters in a consanguineous TC family had hyperphosphatemia and normal 1,25(OH)2D3 levels with characteristic ectopic and vascular calcifications. Interestingly, these patients had low-normal intact serum FGF23 levels but demonstrated FGF23 concentrations approximately 40 times normal when assessed with a C-terminal FGF23 serum assay. Mutational analyses identified a homozygous S71G mutation in FGF23 in the TC patients, which was not found in control alleles. Finally, modeling demonstrated that the S71G mutation most likely destabilizes full-length FGF23. In summary, recessive FGF23 mutations can lead to TC. Additionally, our findings indicate that FGF23 may adopt an unstable conformation in some TC patients, possibly leading to nonfunctional FGF23 protein.
Similar articles
- The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE. Garringer HJ, et al. J Clin Endocrinol Metab. 2006 Oct;91(10):4037-42. doi: 10.1210/jc.2006-0305. Epub 2006 Jul 25. J Clin Endocrinol Metab. 2006. PMID: 16868048 - Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.
Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE. Larsson T, et al. Endocrinology. 2005 Sep;146(9):3883-91. doi: 10.1210/en.2005-0431. Epub 2005 Jun 16. Endocrinology. 2005. PMID: 15961556 - Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, Shaker JL, Econs MJ. Ichikawa S, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4472-5. doi: 10.1210/jc.2006-1247. Epub 2006 Aug 29. J Clin Endocrinol Metab. 2006. PMID: 16940445 - Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ, Imel EA. Folsom LJ, et al. Curr Osteoporos Rep. 2015 Apr;13(2):78-87. doi: 10.1007/s11914-015-0254-3. Curr Osteoporos Rep. 2015. PMID: 25656441 Review.
Cited by
- Serum sclerostin is associated with recurrent kidney stone formation independent of hypercalciuria.
Rodríguez D, Gurevich E, Mohammadi Jouabadi S, Pastor Arroyo EM, Ritter A, Estoppey Younes S, Wagner CA, Imenez Silva PH, Seeger H, Mohebbi N. Rodríguez D, et al. Clin Kidney J. 2023 Nov 1;17(1):sfad256. doi: 10.1093/ckj/sfad256. eCollection 2024 Jan. Clin Kidney J. 2023. PMID: 38186870 Free PMC article. - Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity.
Clinkenbeard E. Clinkenbeard E. Calcif Tissue Int. 2023 Jul;113(1):4-20. doi: 10.1007/s00223-023-01092-1. Epub 2023 Jun 12. Calcif Tissue Int. 2023. PMID: 37306735 Review. - Genome-wide analyses of gene expression profile identify key genes and pathways involved in skeletal response to phosphate and 1,25-dihydroxyvitamin D3 in vivo.
Lee SM, Meyer MB, Benkusky NA, Pike JW. Lee SM, et al. J Steroid Biochem Mol Biol. 2023 Sep;232:106335. doi: 10.1016/j.jsbmb.2023.106335. Epub 2023 May 27. J Steroid Biochem Mol Biol. 2023. PMID: 37245694 Free PMC article. - Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
Puar A, Donegan D, Helft P, Kuhar M, Webster J, Rao M, Econs M. Puar A, et al. AACE Clin Case Rep. 2022 Jul 16;8(5):217-220. doi: 10.1016/j.aace.2022.07.001. eCollection 2022 Sep-Oct. AACE Clin Case Rep. 2022. PMID: 36189136 Free PMC article. - Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism.
Ni P, Clinkenbeard EL, Noonan ML, Richardville JM, McClintick J, Hato T, Janosevic D, Cheng YH, El-Achkar TM, Eadon MT, Dagher PC, White KE. Ni P, et al. Kidney Int. 2021 Mar;99(3):598-608. doi: 10.1016/j.kint.2020.10.024. Epub 2020 Nov 4. Kidney Int. 2021. PMID: 33159963 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources